• Event Type: This was an earnings conference call to discuss the Q2 and H1 FY27 financial results.
  • Date and Time: The conference call was held on November 02, 2026. A specific time was not mentioned in the provided transcript.
  • Purpose: The stated purpose was to discuss the company's financial performance for the second quarter and first half of the fiscal year 2027.
  • Management Participants: The following management members participated:
  • Dr. Krishna Prasad Chigurupati – Chairman and Managing Director
  • Ms. Priyanka Chigurupati – Executive Director
  • Mr. Mukesh Surana – Chief Financial Officer
  • Dr. P.V. Srinivas – Chief Technology Officer
  • Mr. Sanjay Kumar – Chief Executive Officer – Senn Tides India Private Limited

The call was moderated by Ms. Prachi Ambre from MUFG Investor Relations.

  • Availability of Materials: The company had uploaded a detailed quarterly presentation prior to the call. The transcript of the call itself was filed with the exchanges as an enclosure to the regulatory letter.
  • UPSI Statement: The moderator began the call with a standard disclaimer stating that it contained forward-looking statements based on expectations and involved unforeseen risks and uncertainties, which implies that no specific UPSI was shared.

Financial and Operational Highlights

  • Financial Period Discussed: Q2 (Quarter 2) and H1 (Half-Year) of FY27 (Fiscal Year 2027).
  • Financial Performance:
  • Revenue: ₹15,600 million, up 20% YoY and 6% QoQ.
  • EBITDA: ₹3,376 million, up 21% YoY.
  • PAT: ₹1,818 million, up 39% YoY.
  • Gross Margin: 64.4% (down 134 bps YoY, 126 bps QoQ).
  • R&D Expense: ₹885 million (5.7% of sales).
  • Net Cash Position: ₹8,280 million (vs. net debt of ₹1,012 million in Q1).
  • ROCE: 17.6% (up 138 bps YoY).
  • Regulatory Update (Gagillapur Facility): The U.S. FDA conducted a cGMP inspection from October 19 to October 30, 2026. This was the first inspection since a warning letter was issued in February 2025. The inspection concluded with a Form 483 containing eleven observations. Management assessed that none relate to data integrity, cross-contamination, or facility upkeep. They concern investigations, change control, and documentation practices. There is no impact on current manufacturing or distribution. A comprehensive response will be submitted within 15 business days.
  • Business and Strategic Updates:
  • This was the eighth consecutive quarter of sequential revenue growth.
  • Growth was broad-based across key markets (North America, Europe, RoW).
  • The company is pursuing a first-to-file strategy with 3 potential sole first-to-file ANDAs filed in the last 3 quarters (generic DYANAVEL XR, Sodium oxybate ER, Ruxolitinib ER).
  • 26 ANDAs are awaiting approval.
  • The peptide CDMO business (Senn Tides) reported H1 revenue of ₹109 crores with an EBITDA loss of ₹28 crores. The site in Zurich successfully completed a Swissmedic GMP inspection. The focus is on converting a strong inflow of RFPs/RFQs and building an integrated CRDMO platform. A new facility is planned in Vizag, India.
  • Guidance: The company does not provide formal revenue or margin guidance but expressed confidence in continuing the current growth trajectory. For Senn Tides, management is "hopeful" of meeting its target and achieving PAT profitability by the end of FY27.
  • Capex: Planned growth capex of ₹2,000 crores over the next 3-4 years for peptide CDMO, US platform enhancements, oncology, and API expansions.
  • Near-term Launches: 5 product launches planned in the U.S. in the next two quarters (Q3 and Q4), including 2 controlled substances.

Additional Notes Section

  • The document provided is the transcript of the earnings conference call, enclosed with a regulatory submission letter to the exchanges pursuant to SEBI LODR Regulation 46.
  • The transcript contains a full question-and-answer session with analysts, covering topics such as the FDA inspection, margin pressures from geopolitical conflicts, capacity utilization, and the product pipeline.
  • No new financial data was disclosed in this transcript announcement itself; it is a record of the call where previously reported results were discussed.